Public Employees Retirement System of Ohio Sells 8,024 Shares of Seer, Inc. (NASDAQ:SEER)

Public Employees Retirement System of Ohio lessened its stake in shares of Seer, Inc. (NASDAQ:SEER) by 33.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 16,020 shares of the company’s stock after selling 8,024 shares during the period. Public Employees Retirement System of Ohio’s holdings in Seer were worth $32,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC boosted its holdings in shares of Seer by 35.5% during the 2nd quarter. Acadian Asset Management LLC now owns 1,802,106 shares of the company’s stock valued at $3,024,000 after acquiring an additional 472,283 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Seer during the second quarter valued at about $148,000. GSA Capital Partners LLP grew its holdings in shares of Seer by 194.9% during the third quarter. GSA Capital Partners LLP now owns 127,868 shares of the company’s stock worth $252,000 after purchasing an additional 84,515 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Seer in the second quarter valued at approximately $133,000. Finally, XTX Topco Ltd bought a new position in Seer in the 3rd quarter valued at approximately $123,000. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Seer Stock Performance

Shares of NASDAQ SEER opened at $2.31 on Monday. The firm has a 50 day moving average price of $2.24 and a two-hundred day moving average price of $1.93. The stock has a market cap of $136.21 million, a P/E ratio of -1.78 and a beta of 1.58. Seer, Inc. has a 52-week low of $1.51 and a 52-week high of $2.63.

Seer Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.